Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Integromics Partners with CITRE and CEIT

Published: Friday, April 19, 2013
Last Updated: Friday, April 19, 2013
Bookmark and Share
Venture attracts EUR 2 million grant for ‘new frontier’ of data interpretation for drug development.

Integromics® has announced that it has entered into a partnership with the Celgene Institute for Translational Research Europe (CITRE) and the Centre of Studies and Technical Research (CEIT), for the execution of SANSCRIPT, a project that aims at the development of new data analysis methods applied in clinical genomics studies.

Based on the strength of its R&D work, the new partnership has been awarded a EUR two million grant from the Spanish Government for the development of algorithms and statistical tools to identify alternative splicing events significantly related with disease associated biomarkers or therapeutic targets using RNA sequencing (RNA-seq).

Current algorithms, due to their intrinsic characteristics, have major limitations in characterizing gene alterations, which are frequently related to drug resistance and other phenotypes.

Therefore, it is essential to adapt the present methods developed for the new massive sequencing technologies to extract all their potential for development of diagnostic and prognostic tests, and drug discovery in the clinical and pharmaceutical environment.

The SANSCRIPT collaboration, coordinated by Integromics, has been designed to address these issues through the synergy between the engineers at CEIT, scientists at CITRE and the bioinformaticians from Integromics, which will undoubtedly accelerate the development of solutions for personalized medicine.

The new solutions will be validated for personalized-drug development processes where gene expression is essential to understand the differing responses to treatment.

The SANSCRIPT project represents an ideal opportunity for Integromics to reinforce its commitment to the development of software solutions for personalized medicine in the context of clinical studies.

“This is the first time that we can effectively work hand in hand with both an advanced software engineering team from a first class Technical Center and a research group from a leading biopharmaceutical corporation to cooperatively address an important gap”, said Eduardo González Couto, Chief Strategy Officer, Integromics. “The SANSCRIPT grant provides key financial support for us to spearhead the usage of NGS for drug development and help us make personalized medicine a reality.”

“Automated next-gen sequencers have increased the speed and reduced the cost of sequencing, making it possible to offer genetic testing to consumers. Producing the genomic data is not a problem anymore, while the analysis and interpretation of this data has become the ‘new hurdle’ ”, continues Dr. Gonzalez Couto.

Dr. Couto continued, “In order to identify the gene expression changes associated to sensitivity to treatment, including the detailed characterization of transcription isoforms for clinical usage, bioinformatics tools are crucially needed to design novel algorithms from the very beginning to be compatible with long reads from upcoming NGS technologies.”

"For us it is a pleasure to work with both a leading Spanish biosoftware company and a Pharma industry. This collaboration will help us to focus on a specific problem and provide a solution: algorithms that identify gene aberrations related to drug resistance in cancer” said Prof. Angel Rubio, Principal Investigator of the CEIT.

Prof. Rubio continued, “We are quite excited in working to improve the health: even though we have had other projects related with human health, they were not so ambitious as this one” concluded Prof. Rubio.

As genome sequencing continues to take footholds in diagnosis, prognosis and treatment of diseases, it is expected that the findings of the SANSCRIPT project, in terms of software and new methodologies, will enhance the reliability and significance of the next generation sequencing (NGS) technology in the pipelines of drug development and clinical genomics studies.

The results of SANSCRIPT will be made available through new releases of the Integromics’ OmicsOffice® software suite.

This will give clinical drug discovery scientists an immediate access to the fruits of the SANSCRIPT project, allowing them to apply new data analysis methods to their own studies.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Reprogramming Scorpion Venom
‘Twist of nature’ neutralizes toxin.
Tailoring a Suit for Tumor-Penetrating Cancer Meds
For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumors in the body.
Resurrecting an Abandoned Drug
Previously discarded drug shows promise in helping human cells in a lab dish fight off two different viruses.
Safer, Cheaper, Greener and More Efficient System for Organic Synthesis
The new medium not only supports organic synthesis it also produces considerably higher yields of product than pure organic solvents.
Fighting Prostate Cancer
Identifying the most promising compounds which can be used as medications for prostate cancer.
Collaboration to Develop Cancer Therapeutics
Major license agreement with Merck, enabled by Blavatnik Biomedical Accelerator, aims to develop therapy for most common form of acute leukemia.
Faster UVA Molecular Analysis Technology
There are people in the world – chemical engineers, astronomers, national defense scientists investigating an explosion – who need to know just what something is made of, down to the molecular level.
Scientists Synthesize Anti-Cancer Agent
A team led by Rice University synthetic organic chemist K.C. Nicolaou has developed a new process for the synthesis of a series of potent anti-cancer agents originally found in bacteria.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!